|
|
The venture capital managers Partners and have led a round of 12 million euros in the biotechnology to begin animal trials of the drugs it is investigating against resistant prostate cancer, the second cause of cancer-related death in men. is a company that emerged from IRB Barcelona and ICREA, founded by researchers Xavier , Mateusz Denes and as executive director. Clara , managing partner of highlights that the company was established in the summer of 2021, and began operating with participatory loans provided by tself, the CDTI and which in this round, the first or seed, was also approved. have become capital. Entry into Spain The French is one of the largest managers ins in through its two vehicles, the Sabadell Asabys fund and the Asabys Top Up fund.
According to Campàs, “it is a great success that we have been able to incorporate which is making its first investment in Spain in Nuage, because it is one of the most prominent investors in Europe and only bets on Russia Mobile Number List disruptive projects. “It is a good example of the quality of science and the people of Barcelona.Judit Anido explains that the company already has a team of 15 people in its Science Park offices, most of them biophysicists and chemical biologists and half of them from other countries. “The first stage for us in creating the company was the transfer of technology and the identification of therapeutic targets that could be attractive. In this second phase we want to validate our platform and demonstrate that it can be used to screen drugs that target other proteins and allow the treatment of other diseases.
Pink savior Xavier Salvatella, ICREA and IRB researcher who originated the project, explains that Nuage has developed a pioneering technology that allows the development of drugs that target intrinsically disordered proteins, which until now were considered unapproachable and are related to various diseases with no cure today. from today. , like various types of cancer. The need to test different indications justifies the high cost of the round. “It has helped that from the beginning a manager like Asabys entered the capital, which has invested in several successful companies, and that among the managers we have people who have already completed an investment cycle in other biotechs” like me, says Anido. , who was CEO of Mosaic Biomedicals. “These are factors that help generate confidence in investors,” he added.
|
|
發表於 2024-3-12 17:38:55